BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 16044218)

  • 1. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme.
    Singh D; Banerji AK; Dwarakanath BS; Tripathi RP; Gupta JP; Mathew TL; Ravindranath T; Jain V
    Strahlenther Onkol; 2005 Aug; 181(8):507-14. PubMed ID: 16044218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects.
    Dwarakanath BS; Singh D; Banerji AK; Sarin R; Venkataramana NK; Jalali R; Vishwanath PN; Mohanti BK; Tripathi RP; Kalia VK; Jain V
    J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S21-6. PubMed ID: 20009289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioablastoma.
    Prasanna VK; Venkataramana NK; Dwarakanath BS; Santhosh V
    J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S44-7. PubMed ID: 20009294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
    Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?
    Nieder C; Andratschke N; Wiedenmann N; Busch R; Grosu AL; Molls M
    Strahlenther Onkol; 2004 Jul; 180(7):401-7. PubMed ID: 15241527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme.
    Mizumoto M; Tsuboi K; Igaki H; Yamamoto T; Takano S; Oshiro Y; Hayashi Y; Hashii H; Kanemoto A; Nakayama H; Sugahara S; Sakurai H; Matsumura A; Tokuuye K
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):98-105. PubMed ID: 19695794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme.
    Floyd NS; Woo SY; Teh BS; Prado C; Mai WY; Trask T; Gildenberg PL; Holoye P; Augspurger ME; Carpenter LS; Lu HH; Chiu JK; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):721-6. PubMed ID: 14967426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.
    Ford JM; Seiferheld W; Alger JR; Wu G; Endicott TJ; Mehta M; Curran W; Phan SC
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):831-8. PubMed ID: 17560737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA).
    Henriksson R; Capala J; Michanek A; Lindahl SA; Salford LG; Franzén L; Blomquist E; Westlin JE; Bergenheim AT;
    Radiother Oncol; 2008 Aug; 88(2):183-91. PubMed ID: 18336940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative hypofractionated radiotherapy in glioblastoma multiforme.
    Arslan M; Karadeniz AN; Aksu G; Güveli M; Fayda M; Doğan AK; Akyüz F
    J BUON; 2006; 11(1):39-42. PubMed ID: 17318950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.
    Mizoe JE; Tsujii H; Hasegawa A; Yanagi T; Takagi R; Kamada T; Tsuji H; Takakura K;
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):390-6. PubMed ID: 17459607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study.
    Welsh J; Sanan A; Gabayan AJ; Green SB; Lustig R; Burri S; Kwong E; Stea B
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):159-65. PubMed ID: 17331666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A common sense approach to radiotherapy planning of glioblastoma multiforme situated in the temporal lobe.
    Bokstein F; Kovner F; Blumenthal DT; Ram Z; Templehoff H; Kanner AA; Corn BW
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):900-4. PubMed ID: 18407432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
    Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy in supratentorial gliomas. A study of 821 cases.
    Heesters M; Molenaar W; Go GK
    Strahlenther Onkol; 2003 Sep; 179(9):606-14. PubMed ID: 14628126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme.
    Chen AM; Chang S; Pouliot J; Sneed PK; Prados MD; Lamborn KR; Malec MK; McDermott MW; Berger MS; Larson DA
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):825-30. PubMed ID: 17512132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radiotherapy of glioblastoma: is shortening of the treatment time justifiable?].
    Sautter-Bihl ML; Barcsay E; Liebermeister E; Winheller R; Liesegang J; Heinze HG
    Strahlenther Onkol; 1991 Jan; 167(1):7-13. PubMed ID: 1846983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of hemoglobin level prior to radiotherapy on survival in patients with glioblastoma.
    Odrazka K; Petera J; Kohlova T; Dolezel M; Vaculikova M; Zouhar M; Malek V; Hobza V; Latr I; Nemecek S; Sercl M; Ryska P; Blaha M; Cermakova E
    Strahlenther Onkol; 2003 Sep; 179(9):615-9. PubMed ID: 14628127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.